Skip to search formSkip to main contentSkip to account menu

2.5 ML Sodium Hyaluronate 10 MG/ML Prefilled Syringe [Supartz]

Known as: 2.5 ML Supartz 10 MG/ML Prefilled Syringe, SUPARTZ FX 25 MG per 2.5 ML Prefilled Syringe, Supartz 25 MG per 2.5 ML Prefilled Syringe 
National Institutes of Health

Related topics

Related topics

2 relations
Prefilled SyringeSupartz

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A Comparison Between Rheological Properties of Intra-articular Hyaluronic Acid Preparations and Reported Human Synovial Fluid
IntroductionThis study aims to compare the properties of currently available intra-articular hyaluronate (IA-HA) products widely… 
2016
2016
Cost-Effectiveness of Different Forms of Intra-Articular Injections for the Treatment of Osteoarthritis of the Knee
IntroductionOsteoarthritis (OA), as one of the leading causes of disability, decreases the quality of life for those suffering… 
Review
2010
Review
2010
Viscosupplementation in the management of ankle osteoarthritis: a review
IntroductionOsteoarthritis (OA) is a disease of synovial joints and is the most common cause of chronic pain… 
Review
2010
Review
2010
Hyaluronic Acid (Supartz®)
Hyaluronic acid (Supartz®; molecular weight 620–1170 kDa) is a sterile, viscoelastic, non-pyogenic solution that is indicated as… 
Review
2005
Review
2005
(Orthovisc) in osteoarthritis of the knee: a randomized, controlled, multicenter Clinical effects of intraarticular injection of high molecular weight hyaluronan
Objective. To evaluate the efficacy and safety of injection of high molecular weight (HMW) hyaluronan (Orthovisc®) in patients… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)